Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 1, 2006, Pages 62-67

  Estermann, Stephan ^a   Daepp, Gian Carlo ^a   Cattapan Ludewig, Katja ^a   Berkhoff, Magdalena ^a   Frueh, Beatrice E ^a   Goldblum, David ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDICATION; DRUG SELECTIVITY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTION; PUPIL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PIPERIDINES; PUPIL; TREATMENT OUTCOME;

EID: 33644842701     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.62     Document Type: Article

References (42)

1. Leske, M.C. The epidemiology of open-angle glaucoma. Am. J. Epidemiol. 118:116-191, 1983.
2. Tielsch, J.M., Sommer, A., and Katz, J. Racial variations in the prevalence of primary open-angle glaucoma: The Baltimore Eye Survey. JAMA 266:369-374, 1991.
3. Quigley, H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80:389-393, 1996.
4. Quigley, H.A., and Green, W.R. The histology of human glaucoma cupping and optic nerve damage: Clinicopathologic correlation in 21 eyes. Ophthalmology 86:1803-1830, 1979.
5. Armaly, M.F., Krueger D.E., Maunder L., et al. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field - defect. Arch. Ophthalmol. 98:2163-2171, 1980.
6. Brubaker, R.F. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 121:473-483, 1996.
7. Whitehead, A., Perdomo, C., Pratt, R.D., et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: A metaanalysis of individual patient data from randomized, controlled trials. Int. J. Geriatr. Psychiatry 19:624-633, 2004.
8. Goldblum, D., Garweg, J.G., and Böhnke, M. Topical donepezil, a specific acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits. Ophthal. Res. 31(Suppl 1):30, 1999.
9. Goldblum, D., Garweg, J.G., and Böhnke, M. Topical rivastigmine, a specific acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits. J. Ocul. Pharmacol. Ther. 16:29-35, 2000.
10. Takada, Y., Yonezawa, A., Kume, T., et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 306:772-777, 2003.
11. Mekki, Q.A., and Turner, P. Effect of cicloprolol in intraocular pressure in healthy volunteers. Br. J. Clin. Pharmacol. 26,89-91, 1988.
12. Stenkula, E., and Wettrell, K.A. Dose-response study of oral atenolol administered once-daily in patients with raised intraocular pressure. Graefe's Arch. Clin. Exp. Ophthalmol. 218:96-98, 1982.
13. Phillips, C.I., Howitt, G., and Rowland, D.J. Propanolol as ocular hypotensive agent. Br. J. Ophthalmol. 51:222-226, 1967.
14. Jugal Kishore, C., Mishra, Y.C., and Kamlesh, K. A clinical study of effect of oral atenolol on normal intraocular pressure and systemic blood pressure. Ind. J. Ophthalmology 37:179-181, 1989.
15. Aim, A., and Wickström, C.P. Effects of systemic and topical administration of metoprolol on intraocular pressure in healthy subjects. Acta. Ophthalmologica 58, 740-7, 1980.
16. Rogers, S.L., Cooper, N.M., Sukovaty, R., et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br. J. Clin. Pharmacol. 46(Suppl 1):7-12, 1998.
17. Rogers, S.L., Friedhoff, S.T., and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a U.S. multicenter, randomized, double-blind, placebo-controlled trial. Dementia 50:136-145, 1996.
18. Bayer, A.U., Keller, O.N., Ferrari, F., et al. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am. J. Ophthalmol. 133:135-137, 2002.
19. Bayer, A.U., Ferrari, F., and Erb, C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur. Neurol. 47:165-168, 2002.
20. Bayer, A.U., and Ferrari, F. Severe progression of glaucomatous optic neuropathy in patients with Alzheimer's disease. Eye 16:209-212, 2002.
21. McKinnon, S.J., Lehman, D.M., Kerrigan-Baumrind, L.A., et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest. Ophthalmol. Vis. Sci. 43:1077-1087, 2002.
22. Kaufmann, P.L., and Barany, E.H. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgous monkey. Invest. Ophthalmol. 15:793-807, 1976.
23. Berggren, L. Effect of parasympathomimetic and sympathomimetic drugs on secretion in vitro by the ciliary processes of the rabbit eye. Invest. Ophthalmol. 4:91-97, 1965.
24. Gaasterland, D., Kupfer, C., and Ross, K. Studies of aqueous humor dynamics in man: I.V. Effects of pilocarpine upon measurements in young normal volunteers. Invest. Ophthalmol. 14:848-853, 1975.
25. Corey-Bloom J., Anand R., Veach J., for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriatr. Psychopharmakol. 1:55-65, 1998.
26. Fulton B., and Benfield P. Galanthamine. Drugs Aging 9:60-65, 1996.
27. Sherman K.A. Pharmakodynamics of oral E2020 and tacrine in humans: Novel approaches. In: Becker R., Giacobini E., eds. Cholinergic Basis for Alzheimer Therapy. Boston: Birkhäuser, 1991:321-328.
28. Hunter A.J., Murray T.K., Jones J. A., et al. The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br. J. Pharmacol. 98:79-86, 1989.
29. Snape M.F., Anderson S.M.P., Misra A., et al. A comparison of the cholinesterase-inhibitors tacrine and E-2020. Br. J. Pharmacol. 117(Suppl):163P, 1996.
30. Ogura, H., Kosasa, T., Kuriya, Y., et al. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Meth. Find Exp. Clin. Pharmacol. 22:609-613, 2000.
31. Sugimoto, H., Yamanishi, Y., Iimura, Y., et al. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr. Med. Chem. 7:303-339, 2000.
32. Takada, Y., Yonezawa, A., Kume, T., et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 306:772-777, 2003.
33. O'Neill, M.J., Murray, T.K., Lakics, V., et al. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug Targets CNS Neurol. Disord. 1:399-411, 2002.
34. Wehrwein, E., Thompson, S.A., Coulibaly, S.F., et al. Acetylcholine protection of adult retinal ganglion cells from glutamate-induced excitotoxicity. Invest. Ophthalmol. Vis. Sci. 45:1531-1543, 2004.
35. Vickers, J.C. The cellular mechanism underlying neuronal degeneration in glaucoma: Parallels with Alzheimer's disease. Austr. N.Z. J. Ophthalmol. 25:105-109, 1997.
36. Tsai, C.S., Ritch, R., Schwartz, B., et al. Optic nerve head and nerve fiber layer in Alzheimer's disease. Arch. Ophthalmol. 109:199-204, 1991.
37. McKinnon, S.J. Glaucoma: Ocular Alzheimer's disease? Front Biosci. 8:1140-1156, 2003.
38. Hinton, D.R., Sadun, A.A., Blanks, J.C., et al. Optic-nerve degeneration in Alzheimer's Disease. N. Engl. J. Med. 315:485-487, 1986.
39. Blanks, J.C., Torigoe, Y., Hinton, D.R., et al. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol. Aging 17:377-384, 1996.
40. Blanks, J.C., Hinton, D.R., Sadun, A.A., et al. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res. 501:364-372, 1989.
41. Sadun, A.A., and Bassi, C.J. Optic nerve damage in Alzheimer's disease. Ophthalmology 97:9-17, 1990.
42. Kerrigan-Baumrind, L.A., Quigley, H.A., Pease, M.E., et al. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest. Ophthalmol. Vis. Sci. 41:741-748, 2000.